AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02857309 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Optimal medical therapy
Description: OMT using standard heart failure (HF) drugs
Study NCT02857309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy
Description: OMT using standard heart failure (HF) drugs
Study NCT02234830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angioseal closure device
Description: Closure device for femoral artery access closure
Study NCT04550325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kamada Anti-SARS-CoV-2
Description: Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods
Study NCT01695824 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LAA occluder
Description: The procedure is performed under transesophageal echocardiographic (TEE) guidance. After a transseptal puncture is performed, a pigtail catheter is maneuvered into the LAA to perform an LAA angiogram. Through the use of a combination of this angiographic and TEE information, a Watchman device, ranging in size between 21 and 33 mm in diameter, is selected. The device comes prepackaged in a catheter-based delivery system that is advanced into the LAA through a 12F transseptal sheath (outer diameter, 14F). Proper positioning and stability of the device are verified by TEE and angiography before device release.
Study NCT01695824 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA ablation
Description: The left atrium (LA) and pulmonary veins (PVs) were explored through a transseptal approach. Real-time three-dimensional (3D) LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in 1 lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43◦C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43◦C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 seconds. The endpoint of circumferential PV isolation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.
Study NCT00125242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic Feature Analysis (SFA)Training
Description: SFA entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, personal associations, action associated with item). For some participants, treatment items were grouped according to typicality of category membership (e.g,, a robin-typical bird and penguin-atypical bird). Training of atypical items may stimulate a broader semantic activation of the category and thus, may promote greater generalization. Treatment was applied sequentially to sets of items in the context of single-subject, multiple baseline designs. In this way, replication of treatment effects could be evaluated within and across participants. Treatment was administered by certified SLPs three times per week until prescribed accuracy levels were met during nontreatment probes or a maximum number of treatment sessions was completed.
Study NCT01905293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding Study
Study NCT02429037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAd-p53
Description: multi-point injections of rAd-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 10\^12 viral particles (VP) in a 21-days cycle.
Study NCT01435018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (ET)
Description: Beginning on day one of the chemotherapy cycle, ET was given orally in a dose of 50 mg twice daily for 7 consecutive days for the first cycle. If there was no Grade >= 2 toxicity attributable to ET after the first cycle, the dose was escalated to 150 mg daily for 7 days in divided doses of 100 mg/50 mg for the second cycle. After the second cycle, if there was no Grade >= 2 toxicity attributable to ET, the dose was escalated to 100 mg twice daily for 7 days for the third and subsequent cycles.~Treatment with ET was continued for six cycles at the maximum dose achieved or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first.
Study NCT01435018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin and Vincristine (BV)
Description: BV was administered on day one of each chemotherapy cycle.~Vincristine sulfate was administered at a dose of 2 mg (fixed dose) in a volume of 2 mL over 1 minute into the sidearm of a rapidly flowing intravenous infusion every 3 weeks. The vincristine infusion was followed by bleomycin as detailed below.~Bleomycin sulfate was administered at a dose of 15 units/m\^2 over 10 minutes every 3 weeks.~Treatment with BV was continued for six cycles, or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first.
Study NCT01435018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel (PTX)
Description: Paclitaxel was administered by IV infusion in 200 mL, 250 mL, or 500 mL of 5% dextrose or 0.9%Sodium Chloride for injection at a dose of 100 mg/m\^2 body surface area (BSA) every 3 weeks.
Study NCT04784117 — intervention group
Intervention type: OTHER
Intervention: Dispatcher protocol change
Description: In the beginning of 2019 dispatcher protocol was changed to shorten the time of death detection
Study NCT01499121 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sunitinib
Description: The starting dose will be 50 mg Sunitinib on the 28/14 schedule. In patients that develop ≥ grade-2 toxicity after 2 weeks, therapy will be held for 7 days or resolution before continuing therapy according to the 1st dose/schedule change. In patients that do not develop ≥ grade-2 toxicity, therapy will continue for 1-2 weeks or until ≥ grade-2 toxicity. In patients that develop > grade-2 toxicity after less than 4 weeks, therapy will be held for 7 days or before continued according to the 1st dose/schedule change. Patients that do develop grade-2 toxicity (but no more) on the 50 mg 28/14 schedule, will remain on schedule but the time off therapy will be reduced to 7 days if toxicity has resolved after a 7-day break. Patients that develop ≤ grade-1 toxicity on the 50 mg 28/14 schedule, will be dose escalated according to protocol.
Study NCT04043845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib inhibits the function of Bruton's tyrosine kinase (BTK). Ibrutinib blocks signals that stimulate malignant B cells to grow and divide uncontrollably.
Study NCT04043845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
Study NCT01501695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5LGr
Description: Dosage form:Granule Strength:5 gram/sack Dosage:1 sack for patients less than 12 yrs 1.5 sacks for patients 13-18 yrs. Frequency: three times per day. Duration: 8 weeks.
Study NCT01435018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
Description: The following ART regimens were used:~1. EFV/FTC/TDF (Atripla) 200 mg/300 mg/600 mg orally once daily at bedtime or~2. FTC/TDF 200 mg/300 mg (Truvada) orally once daily at bedtime plus EFV (Stocrin) 600 mg orally once daily at bedtime or~3. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or~4. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus PI/r at standard dosing or~5. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus integrase inhibitor at standard dosing
Study NCT01435018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
Description: The following ART regimens were used:~1. EFV/FTC/TDF (Atripla) 200 mg/300 mg/600 mg orally once daily at bedtime or~2. FTC/TDF 200 mg/300 mg (Truvada) orally once daily at bedtime plus EFV (Stocrin) 600 mg orally once daily at bedtime or~3. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or~4. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus PI/r at standard dosing or~5. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus integrase inhibitor at standard dosing
Study NCT00003118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT01695824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin was discontinued in 45 days after procedure in case of no trombus by TE for Watchman group~All patients in Warfarin group continued to receive Warfarin during hole study period with IMR from II to III.
Study NCT03248765 — intervention group
Intervention type: OTHER
Intervention: post-surgical opioid use measured at 1 day and 1 week.
Description: Evaluation of intra-hospital perioperative opioid administration (including intraoperative opioids and Patient Controlled Analgesia (PCA) use). This endpoint is calculated as the total amount of morphine equivalents administered intraoperatively and in the first 24 hours after the end surgery (measured on postoperative day 1).~2) Opioid utilization after discharge from hospital (prescription refills and pills count at subsequent hospital visits). This endpoint is calculated as the total amount of morphine equivalents consumed in the first week after the surgery (measured at 1 week after surgery by electronic questionnaire and verified by direct pill count performed on occasion of the patient's postsurgical visit ).
Study NCT04177680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 pentaenoic acid
Description: Encapsulated omega-3 pentaenoic acid
Study NCT04177680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: icosapent ethyl
Description: Encapsulated omega-3 acid ethyl esters
Study NCT00622011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone and Zotepine for delirium
Description: try risperidone or zotepine in the treatment of delirium
Study NCT00622011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone and Zotepine for delirium
Description: try risperidone or zotepine in the treatment of delirium
Study NCT00003118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00003118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical procedure
Study NCT03401892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
Study NCT03401892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Description: Retinal blood flow will be assessed using FDOCT.
Study NCT01501695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiapride
Description: dosage form: tablet Strength:100 mg Dosage: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Total duration:8 weeks.
Study NCT01501695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: mimetic granule: same with 5LGr mimetic tablet: same with tiapride
Study NCT02006706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000 mg iv Days 1 and 15
Study NCT02006706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 10 - 25 mg/week
Study NCT02006706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion
Study NCT01095757 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Plerixafor
Description: 240 µg/kg subcutaneous injection on the day that the absolute neutrophil count (ANC) is > 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.
Study NCT03401892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Description: Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
Study NCT04378192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask airway
Description: Insertion of laryngeal mask airway before intubation of a morbidly obese patient
Study NCT00003118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical procedure
Study NCT00003118 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00824902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Elastography Imaging
Description: Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
Study NCT04287231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
Study NCT04232397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: anlotinib 8mg qd po
Study NCT04378192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: face mask
Description: use of face mask before intubation of a morbidly obese patient
Study NCT03381547 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegilodecakin
Description: Pegilodecakin Alone
Study NCT00384033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release (DVS SR)
Description: 50 mg tablet, once daily dosing for 8 weeks
Study NCT00384033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release (DVS SR)
Description: 100 mg tablet, once daily dosing for 8 weeks
Study NCT04287231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
Study NCT03789149 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiotherapy
Description: Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG) consisting of a small source of low energy x-rays (30-50 kV) mounted on a mechanical arm with six degrees of freedom. The resulting dose distribution is isotropic around the tip of the X-ray source. A set of spherical applicators with diameters ranging from 1.5 to 5 cm is available to connect to the source. The treatment time may vary from 20-30 minutes with the suggested dose of 18 Gy to the resection cavity to a depth of 1 mm.
Study NCT02993328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN021 Serum
Description: SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
Study NCT02993328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAN021 Placebo
Description: SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
Study NCT02600468 — intervention group
Intervention type: DRUG
Intervention: Orencia
Study NCT00384033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets and capsules, once daily dosing for 8 weeks
Study NCT00384033 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine 60 mg/day
Description: 60 mg capsule, once daily dosing for 8 weeks
Study NCT03181802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: single injection of 200 International Unit of BoNT-A in 10 bilateral paravertebral intramuscular points for treating chronic LBP
Study NCT02915679 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample for genetic purpose, psychiatric assessment and pain investigation
Description: All the participant will performed the same evaluation and blood analysis:~* A clinical assessment by psychiatrics assessing psychiatric disorder and suicidal behavior~* Thermal stimulation for pain assessment~* Computer game named Cyberball: test of social exclusion~* Self report questionnaire for the assessment of reject sensitivity, relationship style, impulsivity, childhood trauma.~* Routine blood sampling
Study NCT02295774 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: standard white light colonoscopy-equivalent to placebo
Description: standard white light colonoscopy
Study NCT02295774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue MMX tablets
Description: 8x25mg methylene blue MMX tablets administered before a colonoscopy
Study NCT02051127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate > 75% of maximum heart rate determined by exercise test before start of the intervention
Study NCT05186610 — intervention group
Intervention type: PROCEDURE
Intervention: FDG PET/CT guided metabolic core needle biopsy
Description: The target lesion to be biopsied was chosen based on accessibility and the highest metabolic activity (Highest standardized uptake value) on FDG PET/CT imaging. The final needle course was based on the anatomic location of the lesion, FDG avidity, and its relation with vital organs. The procedures were performed under full aseptic precautions and under adequate local anesthesia. The biopsy needle was placed to the target lesion using an automated robotic arm (ARA) workstation (ROBIO-EX, Perfint healthcare Pvt Ltd, Chennai, India).
Study NCT01464827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: ABT-450 tablets
Study NCT01068730 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: metformin (Diabex)
Description: Tablets, Oral, 500 mg, Once daily, single dose
Study NCT01068730 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: metformin (Glucophage™)
Description: Tablets, Oral, 500 mg, Once Daily, single dose
Study NCT03181802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 4 ml of physiological serum injected intramuscularly into the lumbar paravertebral muscles.
Study NCT04070625 — intervention group
Intervention type: OTHER
Intervention: Communication book group
Description: Communication book
Study NCT04070625 — intervention group
Intervention type: OTHER
Intervention: Control group
Description: Simple speech therapy
Study NCT01756352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FET
Description: Radiotracer, surrogate marker for protein synthesis
Study NCT01888393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lumacaftor 200 mg q12h + ivacaftor 250 mg q12h
Study NCT01086748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Administered orally.
Study NCT01086748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT01086748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally.
Study NCT04186013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection [Tecentriq]
Description: intravenous infusion of 1.200 mg of Atezolizumab administered intravenously every 3 weeks for a total of 6 doses
Study NCT04186013 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy (EBRT)
Description: 60 Gy of radiotherapy in 30 fractions overs 6 weeks at 2 Gy/day
Study NCT01068730 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: metformin (Glucophage™)
Description: Tablets, Oral, 1000 mg, Once daily, single dose
Study NCT01068730 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: metformin (Diabex)
Description: Tablets, Oral, 1000 mg, Once daily, single dose
Study NCT02313493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby Triple P
Study NCT01653678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D-3 (cholecalciferol), 2000 IU
Study NCT01653678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
Study NCT01653678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D placebo